Stereotactic body radiation therapy after radical prostatectomy: current status and future directions

Le Guevelou, Jennifer; Magne, Nicolas; Counago, Felipe; Magsanoc, Juan Martin; Vermeille, Matthieu; De Crevoisier, Renaud; Benziane-Ouaritini, Nicolas; Ost, Piet; Niazi, Tamim; Supiot, Stéphane; Sargos, Paul

doi:10.1007/s00345-023-04605-7

Cited by 3 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Исследования, посвященные хирургической тактике лечения больных с местно-распространенным РПЖ группы крайне высокого риска прогрессирования, все чаще встречаются в медицинских отчетах. При этом частота положительного хирургического края в этой группе пациентов остается высокой, и около 60-70 % пациентов в последующем требуется проведение дистанционной лучевой терапии (ДЛТ) или андрогендепривационной терапии [8][9][10][11]. Диагностика и лечение опухолей мочеполовой системы.…”

Section: Introductionunclassified

Salvage high-dose rate brachytherapy for local recurrence of prostate cancer after radical prostatectomy

Solodkiy,

Pavlov,

Dzidzaria

et al. 2024

Onkourologiâ

View full text Add to dashboard Cite

Background. The current need for optimization of salvage treatment methods is dictated by the growing expansion of indications for radical prostatectomy in many centers in the developed countries of the world.Aim. To evaluate the effectiveness, toxicity, and technical characteristics of high-dose rate brachytherapy in treatment of local prostate cancer (PCa) recurrences after radical prostatectomy.Materials and methods. Between January 2015 and December 2020, salvage high-dose rate brachytherapy was performed in 17 patients at the Russian Scientific Center of Roentgenology and Radiology for local recurrence of PCa after radical prostatectomy. All patients underwent multiparametric magnetic resonance imaging of the pelvis at the stage of primary diagnosis in order to determine macroscopic tissue component in the prostate bed area. To rule out regional and distant metastases, all patients underwent positron emission tomography with 18F- or 68Ga-labeled prostate-specific membrane antigen. All patients included in the study underwent perineal biopsy of the prostate bed and seminal vesicles.Results. Median follow-up in the treatment group was 35.7 (24–54) months. Overall survival was 100 %. Prostatespecific antigen-specific survival was 88.2 %. There were no local recurrences of PCa in the treatment group. In patients with local PCa recurrence, significant predictors of treatment failure were the presence of clinically extremely high risk of progression at initial diagnosis (p = 0.003), development of biochemical relapse up to 24 months after main treatment (p = 0.001), and increased blood level of prostate-specific antigen above 10 ng/mL during registration of biochemical relapse (p = 0.002).Conclusion. High-dose rate brachytherapy is a safe and effective salvage treatment for local recurrence of PCa after radical prostatectomy. In addition to the brachytherapy technique, the diagnostic stage is also of great importance providing visualization of the exact location of tumor recurrence.

show abstract

Section: Introductionunclassified

Salvage high-dose rate brachytherapy for local recurrence of prostate cancer after radical prostatectomy

Solodkiy,

Pavlov,

Dzidzaria

et al. 2024

Onkourologiâ

View full text Add to dashboard Cite

show abstract

Prostate Cancer Radioligand Therapy

Yechiel,

Chicheportiche,

Keidar

et al. 2024

PET Clinics

View full text Add to dashboard Cite

Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments

Roukoz,

Lazrek,

Bardoscia

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Radical prostatectomy (RP) is one possible curative treatment for localized prostate cancer. Despite that, up to 40% of patients will later relapse. Currently, post-operative radiotherapy (PORT) courses deliver 1.8–2 Gy daily to reach a total dose ranging between 64 and 74 Gy, completed in 7–8 weeks. Several articles reported encouraging data in terms of the effectiveness and the related toxicities using hypofractionation schedules. The objective of the present systematic review was to evaluate the clinical outcomes and toxicity of the use of hypofractionation in adjuvant/salvage prostate cancer treatments. Methods: Medline was searched via PubMed and Scopus from inception to July 2024 to retrieve studies on hypofractionation in adjuvant/salvage prostate cancer treatments. This study was conducted under PRISMA guidelines. Results: A total of 139 articles were identified from the initial search. Subsequently, the 139 studies were reviewed by title and abstract. Ninety-five studies were excluded due to being either abstracts or articles not available in English. In the second step, the full texts of 44 studies were reviewed. Eleven studies were excluded for being reviews, study protocols, or focused on SBRT treatments. Finally, 33 studies were included in our analysis, with a total number of 4269 patients. Of the 33 selected studies, 20 were retrospective trials and 11 were phase I/II prospective trials, while 2 studies were prospective phase III trials. The follow-up ranged from 18 to 217 months. Failure-free survival, for those with the longer follow-up, ranged between 85% and 91% at 3 years, 47 and 78.6% at 5 years and 51.5% at 10 years. Genitourinary (GU) and gastrointestinal acute toxicity was mild to moderate with similar rates across the normofractionated and hypofractionated groups. Acute grade-3 GU toxicity events were unusual, occurring in less than 4% of the cases overall. Conclusion: The present study is the first systematic review of the literature that includes the first two randomized phase III studies published in the literature. Hypofractionated treatment has been shown to be safe, effective, with moderate toxicity and not inferior to conventional RT, with good biochemical control rates.

show abstract

Stereotactic body radiation therapy after radical prostatectomy: current status and future directions

Cited by 3 publications

References 59 publications

Salvage high-dose rate brachytherapy for local recurrence of prostate cancer after radical prostatectomy

Salvage high-dose rate brachytherapy for local recurrence of prostate cancer after radical prostatectomy

Prostate Cancer Radioligand Therapy

Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments

Contact Info

Product

Resources

About